Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shelby Shimberg

Physician Assistant, Surgical Atlanta, GA Physician Assistant

NPI 1265022537 CMS profile 11125443

1450 S Johnson Ferry Rd, Atlanta, GA 30319

Open in the dashboard

General payments

$7,627

195 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shelby Shimberg of Atlanta, GA is reported in the CMS Open Payments database as having received $7,627 across 195 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,319 46
2024 General $2,258 40
2023 General $1,243 34
2022 General $1,410 43
2021 General $1,397 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shelby Shimberg
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Shelby Shimberg were reported at $1,319. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Shelby Shimberg Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,397 $111 $36–$285 $132
2022 $1,410 $126 $44–$350 $149
2023 $1,243 $137 $47–$355 $160
2024 $2,258 $146 $49–$384 $164
2025 $1,319 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,745 20 payments
  2. Teleflex LLC $1,405 17 payments
  3. Janssen Biotech, Inc. $417 4 payments
  4. Endo Pharmaceuticals Inc. $395 15 payments
  5. Sumitomo Pharma America, Inc. $372 20 payments
  6. Myovant Sciences Inc. $345 12 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $321 15 payments
  8. Coloplast Corp $294 7 payments
  9. Merck Sharp & Dohme Corporation $234 9 payments
  10. Antares Pharma, Inc. $202 11 payments
  11. Other $1,895 65 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,450 191 payments
  2. Education $177 4 payments
Products named General payments · program years 2021–2025
  1. INTERSTIM $1,745 20 payments
  2. UROLIFT $537 7 payments
  3. ORGOVYX $510 22 payments
  4. XIAFLEX $473 18 payments
  5. ERLEADA $417 4 payments
  6. Xofigo $287 13 payments
  7. UroLift System $284 3 payments
  8. Titan $273 6 payments
  9. Nubeqa $259 12 payments
  10. XTANDI $247 9 payments
  11. Other $3,408 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

515

Median for Physician Assistant: 241

Drug cost

$44,998

Median for Physician Assistant: $4,110

Branded share of claims

39.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 21 $18,123
Myrbetriq Mirabegron Brand 20 $14,281
Methenamine Hippurate Generic 108 $4,462
Yuvafem Estradiol Brand 23 $2,119
Estradiol Generic 20 $1,666
Trimethoprim Generic 17 $881
Solifenacin Succinate Generic 15 $709
Alfuzosin Hcl Er Alfuzosin Hcl Brand 31 $706
Finasteride Generic 44 $521
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 11 $421

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$34,781

Medicare's payments for the services billed

Medicare patients

259

Average age 77

Services billed

792

87 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 42%
Diabetes 27%
Atrial fibrillation 25%
Chronic kidney disease 25%
Cancer 19%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ERLEADA
  • Janssen Biotech, Inc. $234
$234 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $82
  • PFIZER INC. $17
$99 — —
AKEEGA
  • Janssen Biotech, Inc. $84
$84 — —
XYOSTED
  • Antares Pharma, Inc. $37
$37 — —
XTANDI
  • PFIZER INC. $17
  • Astellas Pharma US Inc $16
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record